Developing Technology to Improve the Detection of Cancer and Enhance Therapeutic Effectiveness
Armune BioScience scientifically researches and develops diagnostic and prognostic tests for prostate, lung, and breast cancers that may allow physicians and patients to make more personalized treatment decisions for a better prognosis. Our technology is based on evidence that the immune system’s early warning signals provide critical biological insight to improve cancer detection and enhance therapeutic effectiveness.
The company has developed the peer-reviewed and validated prostate-cancer-risk-assessment technology APIFINY®—a cancer specific non-PSA blood test that may aid clinicians in the assessment of risk for the presence of prostate cancer. The product is immediately available to physicians for clinical use.
Ongoing research based on Armune’s proprietary serum technology is focused on developing:
- Improvements in the early detection of cancer to improve survival rates.
- Monitoring tools on cancer progression from indolent to aggressive disease.
- Risk-assessment tools for lung and breast cancers. In the U.S., lung cancer is the leading cause of cancer deaths. Breast cancer is the most commonly diagnosed cancer in U.S. women, and, after lung cancer, is the second leading cause of cancer deaths in women.
- Enhanced tools to identify appropriate patients for immunotherapy and monitor cancer therapeutic effectiveness.
Armune BioScience technology is based on research performed at the University of Michigan under the direction of Dr. Arul Chinnaiyan and by Dr. David George Beer, PhD., Professor of Surgery, Section of Thoracic Surgery. Armune BioScience has secured an exclusive license from the University of Michigan for this technology. Three U.S. and two foreign patents have been issued. The company was founded by members of the Apjohn Group, LLC, a business accelerator that brings together valuable resources of management talent and angel/seed financing. The company’s corporate headquarters are in Kalamazoo, MI and the laboratory is in Ann Arbor, MI.
The Armune BioScience Laboratory is a commercial reference laboratory, certified and regulated by the federal Clinical Laboratory Improvement Amendments (CLIA) law established in 1988 (CLIA ’88). The laboratory’s CLIA Certificate permits it to perform APIFINY and other high-complexity medical tests.
Supporting Research for the Armune Methodology of Detecting Cancer:
- “Novel Prostate Cancer Biomarkers Derived from Autoantibody Signatures,” (Translational Oncology (2015) 8, 106–111)
- “Autoantibody Signatures in Prostate Cancer,” The New England Journal of Medicine, (NEJM 2005; 353:1224-1235)
- “Autoantibody Profiles Reveal Ubiquilin 1 as a Humoral Immune Response Target in Lung Adenocarcinoma,” Cancer Journal – American Association for Cancer Research (Cancer Res 2007;67(7):3461–7)